Nivalis Therapeutics President and Head of Research and Development Stanford Peng's 2018 pay jumps 273% to $2M
Nivalis Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 24, 2019
Nivalis Therapeutics reported fiscal year 2018 executive compensation information on April 24, 2019.
In 2018, four executives at Nivalis Therapeutics received on average a compensation package of $1.2M, a 20% increase compared to previous year.
Average pay of disclosed executives at Nivalis Therapeutics
Stanford Peng, President and Head of Research and Development, received $2M in total, which increased by 273% compared to 2017. 75% of Peng's compensation, or $1.5M, was in option awards. Peng also received $103K in non-equity incentive plan and $400K in salary.
Mitchell H. Gold, Chief Executive Officer, received a compensation package of $1M, which decreased by 56% compared to previous year. 49% of the compensation package, or $513K, was in option awards.
Mark Litton, Chief Operating Officer, earned $985K in 2018.
Paul Rickey, Chief Financial Officer, received $751K in 2018, which increases by 50% compared to 2017.
Related executives
You may also like
Source: SEC filing on April 24, 2019.